| abstract |
The present invention generally relates to the fields of medicine and pharmacy. More specifically, it relates to novel galanin analogs and their use in therapy. The present invention provides cyclic peptide analogs of galanin, wherein the galanin analog includes a (methyl)lanthionine bridge, and wherein the analog has the general formula "X1-X2-X3-X4-X5-X6- X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-", or those lacking X1 and/or up to 11 C-terminal residues Truncated variants, wherein two residues selected from X3, X4, X6, X7, X10 and X13-X19 together form a lanthionine bridge of structure Ala-S-Ala or structure Abu-S-Ala or Ala Methyllanthionine bridge of ‑S‑Abu. |